Jae-Sook Ahn1, Sung-Hoon Jung1, Deok-Hwan Yang1, Soo-Young Bae2, Yeo-Kyeoung Kim1, Hyeoung-Joon Kim1, Je-Jung Lee3. 1. Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Republic of Korea. 2. Department of Hematology-Oncology, St Carollo Hospital, Suncheon-si, Jeollanam-do, Republic of Korea. 3. Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Republic of Korea. Electronic address: drjejung@chonnam.ac.kr.
Abstract
INTRODUCTION: Bortezomib-based therapy is commonly used in treatment for relapsed or refractory multiple myeloma (MM). Unfortunately, many patients show relapse or progression in heterogeneous patterns. PATIENTS AND METHODS: In this study, we retrospectively evaluated patterns of relapse or progression after bortezomib-based salvage therapy in patients with MM and analyzed prognostic significance according to patterns of relapse or progression. One hundred forty-eight patients were treated with bortezomib-based therapy between November 2004 and April 2012. Of these patients, 104 (70.3%) patients relapsed or progressed after bortezomib-based salvage therapy. We divided the patterns of relapse or progression to the 2 groups: (1) the isoform relapse or progression (group A) in 89 (85.6%) patients as disease findings at initiation of bortezomib-based therapy; and (2) transformed relapse or progression (group B) in 15 (14.4%) patients (plasmacytoma, n = 7; light chain escape, n = 6; and plasma cell leukemia, n = 2) different from initial disease findings. RESULTS: Median overall survival in group A and group B were 32.7 months (95% confidence interval [CI], 21.3-44.1) and 10.7 months (95% CI, 2.0-19.4) (P < .001), respectively. CONCLUSION: MM patients who relapsed or progressed as the transformed pattern for bortezomib-based salvage therapy have an extremely poor prognosis and might require new innovative approaches.
INTRODUCTION:Bortezomib-based therapy is commonly used in treatment for relapsed or refractory multiple myeloma (MM). Unfortunately, many patients show relapse or progression in heterogeneous patterns. PATIENTS AND METHODS: In this study, we retrospectively evaluated patterns of relapse or progression after bortezomib-based salvage therapy in patients with MM and analyzed prognostic significance according to patterns of relapse or progression. One hundred forty-eight patients were treated with bortezomib-based therapy between November 2004 and April 2012. Of these patients, 104 (70.3%) patients relapsed or progressed after bortezomib-based salvage therapy. We divided the patterns of relapse or progression to the 2 groups: (1) the isoform relapse or progression (group A) in 89 (85.6%) patients as disease findings at initiation of bortezomib-based therapy; and (2) transformed relapse or progression (group B) in 15 (14.4%) patients (plasmacytoma, n = 7; light chain escape, n = 6; and plasma cell leukemia, n = 2) different from initial disease findings. RESULTS: Median overall survival in group A and group B were 32.7 months (95% confidence interval [CI], 21.3-44.1) and 10.7 months (95% CI, 2.0-19.4) (P < .001), respectively. CONCLUSION: MM patients who relapsed or progressed as the transformed pattern for bortezomib-based salvage therapy have an extremely poor prognosis and might require new innovative approaches.
Authors: J Laubach; L Garderet; A Mahindra; G Gahrton; J Caers; O Sezer; P Voorhees; X Leleu; H E Johnsen; M Streetly; A Jurczyszyn; H Ludwig; U-H Mellqvist; W-J Chng; L Pilarski; H Einsele; J Hou; I Turesson; E Zamagni; C S Chim; A Mazumder; J Westin; J Lu; T Reiman; S Kristinsson; D Joshua; M Roussel; P O'Gorman; E Terpos; P McCarthy; M Dimopoulos; P Moreau; R Z Orlowski; J S Miguel; K C Anderson; A Palumbo; S Kumar; V Rajkumar; B Durie; P G Richardson Journal: Leukemia Date: 2015-12-29 Impact factor: 11.528
Authors: Aurelio Lopez; Maria-Victoria Mateos; Albert Oriol; Marta Valero; Joaquín Martínez; Jose Ignacio Lorenzo; Montserrat Perez; Rafael Martinez; Raquel de Paz; Miguel Granell; Felipe De Arriba; M Jesús Blanchard; Francisco Javier Peñalver; Jose Luis Bello; Maria Luisa Martin; Joan Bargay; Joan Blade; Juan Jose Lahuerta; Jesús F San Miguel; Javier de la Rubia Journal: Leuk Res Rep Date: 2015-09-24